No Data
Express News | Sichuan Kelun Pharmaceutica Says Five Company Products Include in China Drug Catalog
Sichuan Kelun Pharmaceutical (002422.SZ) pharmaceuticals included in the national medical insurance catalog.
sichuan kelun pharmaceutical (002422.SZ) announced that on November 28, 2024, the National Medical Insurance Administration and the Ministry of Human Resources...
Sichuan Kelun Pharmaceutical (002422.SZ): The core product Lukan Sanduo Monoclonal Antibody (sac-TMT) of its subsidiary, based on the OptiTROP-Breast01 study, has been approved by the National Drug Administration for the treatment of second-line and above
On November 27, Kelun Pharmaceutical announced that Sichuan Kelun Pharmaceutical Co., Ltd. (referred to as the "Company") recently learned that its controlling subsidiary Sichuan Kelun Botai Biomedical Co., Ltd. (referred to as "Kelun Botai") released the first domestically produced antibody-drug conjugate (ADC) Lushan Shatu Pertuzumab targeting the human zygote nourishing cell surface antigen 2 (TROP2) for adult patients with unresectable local advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic treatments (with at least one treatment targeting the advanced or metastatic stage).
While Institutions Invested in Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Benefited From Last Week's 3.3% Gain, Retail Investors Stood to Gain the Most
Sichuan Kelun Pharmaceutical (002422.SZ): Its subsidiary Kelun Bo Tai has signed an exclusive license agreement with the affiliated hospital of Southwest Medical University on the radiopharmaceutical conjugate TBM-001.
On November 20, Gelonghui reported that Sichuan Kelun Pharmaceutical (002422.SZ) stated on the investor interaction platform that its subsidiary Kelun Botai has signed an exclusive license agreement with the Affiliated Hospital of Southwest Medical University regarding the radioactive nuclide drug conjugate TBM-001, and has initiated the collaborative development of other RDC drugs to address unmet clinical needs, besides TBM-001.
Sichuan Kelun Pharmaceutical (002422.SZ): Currently, 264 is in the normal review process.
Gelonghui, November 20 - Sichuan Kelun Pharmaceutical (002422.SZ) stated on the investor interaction platform on November 20 that 264 is currently in the normal review process.
Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/ENo Data
No Data
